Evidence map›Paper›PMID 31024530›Full record

ArticleFrontiers in immunology2019

Tumor-Associated Disialylated Glycosphingolipid Antigen-Revealing Antibodies Found in Melanoma Patients' Immunoglobulin Repertoire Suggest a Two-Direction Regulation Mechanism Between Immune B Cells and the Tumor.

Beatrix Kotlan, Szabolcs Horvath, Klara Eles, Vanda K Plotar, Gyorgy Naszados, Katalin Czirbesz, Miri Blank, Emil Farkas, Laszlo Toth, Jozsef Tovari and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Beatrix KotlanMolecular Immunology and Toxicology, National Institute of Oncology, Budapest, Hungary.
Szabolcs HorvathCenter of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary.
Klara ElesCenter of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary.
Vanda K PlotarCenter of Surgical and Molecular Pathology, National Institute of Oncology, Budapest, Hungary.
Gyorgy NaszadosCenter of Image Analysis and Radiological Diagnostics, National Institute of Oncology, Budapest, Hungary.
Katalin CzirbeszDepartment of Oncodermatology, National Institute of Oncology, Budapest, Hungary.
Miri BlankZabludowitz Center for Autoimmune Diseases, Sheba Medical Center Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Emil FarkasCenter of Oncosurgery, National Institute of Oncology, Budapest, Hungary.
Laszlo TothCenter of Oncosurgery, National Institute of Oncology, Budapest, Hungary.
Jozsef TovariDepartment of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.
Andras SzekacsAgro-Environmental Research Institute, National Agricultural Research and Innovation Centre, Budapest, Hungary.
Yehuda ShoenfeldZabludowitz Center for Autoimmune Diseases, Sheba Medical Center Affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Maria GodenyCenter of Image Analysis and Radiological Diagnostics, National Institute of Oncology, Budapest, Hungary.
Miklos KaslerNational Institute of Oncology, Budapest, Hungary.
Gabriella LiszkayDepartment of Oncodermatology, National Institute of Oncology, Budapest, Hungary.
National Institute of Oncology · HUNational Agricultural Research and Innovation Centre · HUSheba Medical Center · ILTel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is far less information available about the tumor infiltrating B (TIL-B) cells, than about the tumor infiltrating T cells. We focused on discovering the features and potential role of B lymphocytes in solid tumors. Our project aimed to develop innovative strategies to define cancer membrane structures. We chose two solid tumor types, with variable to considerable B cell infiltration. The strategy we set up with invasive breast carcinoma, showing medullary features, has been introduced and standardized in metastatic melanoma. After detecting B lymphocytes by immunohistochemistry, VH-JH, Vκ-Jκ immunoglobulin rearranged V region genes were amplified by RT-PCR, from TIL-B cDNA. Immunoglobulin variable-region genes of interest were cloned, sequenced, and subjected to a comparative DNA analysis. Single-chain variable (scFv) antibody construction was performed in selected cases to generate a scFv library and to test tumor binding capacity. DNA sequence analysis revealed an overrepresented VH3-1 cluster, represented both in the breast cancer and the melanoma TIL-B immunoglobulin repertoire. We observed that our previously defined anti GD3 ganglioside-binder antibody-variable region genes were present in melanoma as well. Our antibody fragments showed binding potential to disialylated glycosphingolipids (GD3 ganglioside) and their O acetylated forms on melanoma cancer cells. We conclude that our results have a considerable tumor immunological impact, as they reveal the power of TIL-B cells to recognize strong tumor-associated glycosphingolipid structures on melanomas and other solid tumors. As tumor-derived gangliosides affect immune cell functions and reduce the B lymphocytes' antibody production, we suspect an important B lymphocyte and cancer cell crosstalk mechanism. We not only described the isolation and specificity testing of the tumor infiltrating B cells, but also showed the TIL-B cells' highly tumor-associated GD3 ganglioside-revealing potential in melanomas. The present data help to identify new cancer-associated biomarkers that may serve for novel cancer diagnostics. The two-direction regulation mechanism between immune B cells and the tumor could eventually be developed into an innovative cancer treatment strategy.

Indexed as

B-LymphocytesBreast NeoplasmsCell Line, TumorGangliosidesHumansLymphocytes, Tumor-InfiltratingMelanomaSingle-Chain Antibodiesganglioside, GD3GangliosidesSingle-Chain AntibodiesB lymphocytesglycosphingolipids (GSLs)immune regulationimmunoglobulinmetastatic melanomasnatural antibodytumor-associated antigen

Identifiers

PMID31024530
PMCPMC6459966
OpenAlexW2925351158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.